Synthesis, libelling and bio-distribution of cerebral radiopharmaceuticals with Technetium 99

The prevalence of brain pathologies especially neurodegenerative diseases still increasing due to longer life expectancy and the age pyramid evolution that shows an increase in the proportion of the old persons. So, we count currently more than 30 million persons affected by a neuro-degenerative disease. It is estimated that this number will reach 100 million at 2050. Generally, these diseases are not fatal, but the intellectual handicap and/or the progressive physical deterioration which causes some of them (Alzheimer, Parkinson), may lead to the death. Despite the screening efforts, it remains difficult to establish an early and differential diagnosis. It is proposed that research provides new solutions for diagnostic to reduce the risk of mortality associated with these diseases and improve patient comfort. The first part of this presentation is dedicated to some definitions of the radiopharmaceuticals, the chemistry of technetium and rhenium and the strategies of labeling with Technetium. We propose first to give an overview concerning the target vectors and criteria for crossing of the hemato-encephalic barrier. In the second part we will present our results concerning the synthesis and the physico-chemical characterization of some ferrocenic ligands, radio-complex of the technetium-99 and their "rhenisted" analogues. We will expose some bio-distributions as well as the biochemical studies of certain cytectrenic molecules which showed a very interesting affinity for 5HT1A serotonergic receptors such as Tc-MP associated to the molecule of piperazine (2 - methoxyphenyl) as a vector of choice. This molecule allows an exceptional kinetic of extraction around (2.47 pou cent DI / g) in 5min pi. (Author)